Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Current Liabilities (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Total Current Liabilities for 4 consecutive years, with $378.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 64.64% to $378.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $378.8 million through Dec 2025, up 64.64% year-over-year, with the annual reading at $378.8 million for FY2025, 64.64% up from the prior year.
  • Total Current Liabilities hit $378.8 million in Q4 2025 for Axsome Therapeutics, up from $360.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $378.8 million in Q4 2025 to a low of $24.5 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $173.4 million across 4 years, with a median of $141.5 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: soared 309.99% in 2023 and later skyrocketed 43.11% in 2024.
  • Year by year, Total Current Liabilities stood at $96.6 million in 2022, then soared by 43.8% to $138.9 million in 2023, then soared by 65.72% to $230.1 million in 2024, then skyrocketed by 64.64% to $378.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for AXSM at $378.8 million in Q4 2025, $360.3 million in Q3 2025, and $342.1 million in Q2 2025.